Modern Inflammatory Phenotyping of Asthma. Breathomics Is Here to Stay.
作者信息
Sterk Peter J
机构信息
1Amsterdam UMCUniversity of AmsterdamAmsterdam, the Netherlands.
出版信息
Am J Respir Crit Care Med. 2019 Aug 15;200(4):405-406. doi: 10.1164/rccm.201904-0733ED.
Abstract
摘要
相似文献
1
Modern Inflammatory Phenotyping of Asthma. Breathomics Is Here to Stay.
Am J Respir Crit Care Med. 2019 Aug 15;200(4):405-406. doi: 10.1164/rccm.201904-0733ED.
2
Breathomics from exhaled volatile organic compounds in pediatric asthma.
Pediatr Pulmonol. 2017 Dec;52(12):1616-1627. doi: 10.1002/ppul.23785. Epub 2017 Oct 30.
3
Exhaled volatile organic compounds in adult asthma: a systematic review.
Eur Respir J. 2019 Sep 29;54(3). doi: 10.1183/13993003.00056-2019. Print 2019 Sep.
4
Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label.
Eur Respir J. 2018 Jan 11;51(1). doi: 10.1183/13993003.01817-2017. Print 2018 Jan.
5
Breathomics in the setting of asthma and chronic obstructive pulmonary disease.
J Allergy Clin Immunol. 2016 Oct;138(4):970-976. doi: 10.1016/j.jaci.2016.08.004. Epub 2016 Aug 31.
6
Asthma breathomics-promising biomarkers in need of validation.
Pediatr Pulmonol. 2018 Mar;53(3):263-265. doi: 10.1002/ppul.23941. Epub 2018 Jan 23.
7
Breathomics and treatable traits for chronic airway diseases.
Curr Opin Pulm Med. 2019 Jan;25(1):94-100. doi: 10.1097/MCP.0000000000000534.
8
Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises.
Trends Mol Med. 2015 Oct;21(10):633-644. doi: 10.1016/j.molmed.2015.08.001.
9
Volatile organic compounds associated with diagnosis and disease characteristics in asthma - A systematic review.
Respir Med. 2020 Aug;169:105984. doi: 10.1016/j.rmed.2020.105984. Epub 2020 May 16.
10
Exhaled volatile organic compounds for better asthma control: could it be a future noninvasive adherence test?
Eur Respir J. 2020 Feb 27;55(2). doi: 10.1183/13993003.02112-2019. Print 2020 Feb.
引用本文的文献
1
Biologics in Asthma: A Molecular Perspective to Precision Medicine.
Front Pharmacol. 2022 Jan 19;12:793409. doi: 10.3389/fphar.2021.793409. eCollection 2021.
2
Hypersensitivity Reactions: An Everyday Occurrence in Pediatric Allergy Clinics.
Pediatr Allergy Immunol Pulmonol. 2020 Mar;33(1):12-18. doi: 10.1089/ped.2019.1109. Epub 2020 Mar 2.
3
Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort.
Eur Respir J. 2021 Feb 11;57(2). doi: 10.1183/13993003.02127-2020. Print 2021 Feb.
本文引用的文献
1
Exhaled Volatile Organic Compounds Are Able to Discriminate between Neutrophilic and Eosinophilic Asthma.
Am J Respir Crit Care Med. 2019 Aug 15;200(4):444-453. doi: 10.1164/rccm.201811-2210OC.
2
Stratification of asthma phenotypes by airway proteomic signatures.
J Allergy Clin Immunol. 2019 Jul;144(1):70-82. doi: 10.1016/j.jaci.2019.03.013. Epub 2019 Mar 28.
3
From Big Data to Precision Medicine.
Front Med (Lausanne). 2019 Mar 1;6:34. doi: 10.3389/fmed.2019.00034. eCollection 2019.
4
Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma.
J Allergy Clin Immunol. 2019 May;143(5):1811-1820.e7. doi: 10.1016/j.jaci.2018.10.058. Epub 2018 Dec 6.
5
Breathomics and treatable traits for chronic airway diseases.
Curr Opin Pulm Med. 2019 Jan;25(1):94-100. doi: 10.1097/MCP.0000000000000534.
6
Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis.
Thorax. 2018 Dec;73(12):1110-1119. doi: 10.1136/thoraxjnl-2018-211540. Epub 2018 Jun 1.
7
Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label.
Eur Respir J. 2018 Jan 11;51(1). doi: 10.1183/13993003.01817-2017. Print 2018 Jan.
8
T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED.
Eur Respir J. 2017 Feb 8;49(2). doi: 10.1183/13993003.02135-2016. Print 2017 Feb.
9
Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises.
Trends Mol Med. 2015 Oct;21(10):633-644. doi: 10.1016/j.molmed.2015.08.001.
10
Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
J Intern Med. 2016 Feb;279(2):192-204. doi: 10.1111/joim.12382. Epub 2015 Jun 15.
Zotero 插件